{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:58:48Z","timestamp":1753437528633,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:00:00Z","timestamp":1545696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIAID"},{"name":"NIH"},{"name":"Human Sciences Foundation"},{"DOI":"10.13039\/501100007077","name":"NIBIO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labor, and Welfare of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.antiviral.2018.12.012","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T01:05:44Z","timestamp":1545440744000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of 4-oxoquinolines, a new chemical class of anti-HIV-1 compounds"],"prefix":"10.1016","volume":"162","author":[{"given":"Tomomi","family":"Shiroishi-Wakatsuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Maejima-Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Sukegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Ode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Hachiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Imahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-4828","authenticated-orcid":false,"given":"Yasumasa","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.12.012_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib2","first-page":"52","article-title":"Nonclassical biological activities of quinolone derivatives","volume":"15","author":"Ahmed","year":"2012","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.antiviral.2018.12.012_bib3","first-page":"1097","article-title":"Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives","volume":"53","author":"Baba","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1128\/AAC.41.6.1250","article-title":"Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives","volume":"41","author":"Baba","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tim.2016.01.006","article-title":"HIV-1 reservoirs during suppressive therapy","volume":"24","author":"Barton","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib6","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/JVI.68.4.2726-2730.1994","article-title":"Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency","volume":"68","author":"Butera","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/JCM.01708-06","article-title":"Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs","volume":"45","author":"Chiba-Mizutani","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkv012","article-title":"Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region","volume":"70","author":"Danion","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib9","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1016\/j.bmcl.2012.06.020","article-title":"Oxoquinoline acyclonucleoside phosphonate analogues as a new class of specific inhibitors of human immunodeficiency virus type 1","volume":"22","author":"Faro","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2018.12.012_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00315-17","article-title":"Impact of HIV-1 integrase L74F and V75I mutations in a clinical isolate on resistance to second-generation integrase strand transfer inhibitors","volume":"61","author":"Hachiya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dku387","article-title":"Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance","volume":"70","author":"Hardy","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.3646751","article-title":"Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms","volume":"236","author":"Koyanagi","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.12.012_bib14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.12.012_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"Markowitz","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.12.012_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2018.12.012_bib17","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.3390\/v7072790","article-title":"Resistance against integrase strand transfer inhibitors and relevance to HIV persistence","volume":"7","author":"Mesplede","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.12.012_bib18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bmcl.2010.11.108","article-title":"6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors","volume":"21","author":"Nagasawa","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2018.12.012_bib19","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1021\/jm8003784","article-title":"Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors","volume":"51","author":"Pasquini","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.12.012_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.12.012_bib21","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1016\/j.bmc.2009.06.037","article-title":"Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives","volume":"17","author":"Santos","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.12.012_bib22","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1021\/jm900460z","article-title":"Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors","volume":"52","author":"Sato","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.12.012_bib23","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/jm0600139","article-title":"Novel HIV-1 integrase inhibitors derived from quinolone antibiotics","volume":"49","author":"Sato","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.12.012_bib24","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2018.12.012_bib25","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.12.012_bib26","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1021\/jm701585h","article-title":"Structure-activity relationship study on anti-HIV 6-desfluoroquinolones","volume":"51","author":"Tabarrini","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.12.012_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.coviro.2012.08.007","article-title":"The development of novel HIV integrase inhibitors and the problem of drug resistance","volume":"2","author":"Wainberg","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.12.012_bib28","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.12.012_bib29","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.12.012_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/095632020501600603","article-title":"A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity","volume":"16","author":"Yan","year":"2005","journal-title":"Antiviral Chem. Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T23:46:23Z","timestamp":1662680783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218304261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"alternative-id":["S0166354218304261"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.012","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 4-oxoquinolines, a new chemical class of anti-HIV-1 compounds","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}